Combination DMARD therapy with hydroxychloroquine, sulfasalazine, and methotrexate

J.R. O’Dell

ABSTRACT
Triple combination therapy with hydroxychloroquine, sulfasalazine, and methotrexate (MTX) has been shown in double-blind, placebo-controlled studies to be significantly superior to MTX alone (Paulus 50% responses of 77% versus 33%). In long-term follow-up studies, this therapy has now been shown to be well-tolerated with continued efficacy in the majority of patients.

Key words
Rheumatoid arthritis, combination, DMARD, hydroxychloroquine, sulfasalazine, methotrexate.

Please address correspondence and reprint requests to: Dr. James R. O’Dell, Section of Rheumatology, Department of Internal Medicine, 983025 Nebraska Medical Center, Omaha, Nebraska 68198-3025, USA.

Clin Exp Rheumatol 1999; 17 (Suppl. 18): S53 - S58.
© Copyright Clinical and Experimental Rheumatology 1999.